Zevra Therapeutics ($ZVRA) Insider Trading & Smart Money Activity
Zevra Therapeutics, Inc. ($ZVRA) has 4 insider trades and 9 analyst ratings on file. In the last 12 months on the open market, no insider bought and 2 insiders sold ($663.13K), net -$663.13K.
- Insider buyers (12 mo)
- 0
- Insider sellers (12 mo)
- 2
- Net insider $ (12 mo)
- -$663.13K
- Congress trades (12 mo)
- 0
- 13F moves on file
- 0
- Analyst ratings on file
- 9
ZVRA insider buying and selling by quarter
| Quarter | Insider buys | Insider sales | Congress buys / sales | 13F added / cut |
|---|---|---|---|---|
| Q1 2026 | 0 | 0 | 0 / 0 | 0 / 0 |
| Q2 2026 | 0 | 1 · $438.18K | 0 / 0 | 0 / 0 |
| Q3 2026 | 0 | 0 | 0 / 0 | 0 / 0 |
| Q4 2026 | 0 | 1 · $224.95K | 0 / 0 | 0 / 0 |
Insider buys and sales count open-market trades only (Form 4 codes P and S). Grants, option exercises and tax withholding are left out.
All ZVRA insider, congress, 13F and analyst activity
| Date | Source | Who | Action | Shares | Value / amount | ΔOwn | 1W | 1M | 6M | Filing | Story |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Insider | McFarlane Neil F.President and CEO | Sell (Open-market sale) 10b5-1 | 20K sh | $224.95K | Read | ||||||
| Analyst | HC Wainwright | Reiterates to buy | PT $26 | +10.3% | -3.7% | Read | |||||
| Insider | Rahsaan ThompsonChief Legal & Compliance | Sell (Open-market sale) 10b5-1 | 34.56K sh | $438.18K | +10.8% | -4.0% | — | ||||
| Insider | Rahsaan ThompsonChief Legal & Compliance | Sell (Option exercise) | 66.67K sh | +10.8% | -1.6% | — | |||||
| Insider | Rahsaan ThompsonChief Legal & Compliance | Buy (Option exercise) | 66.67K sh | +10.8% | -1.6% | — | |||||
| Analyst | Canaccord Genuity | Reiterates to buy | PT $29 | -0.5% | +1.6% | Read | |||||
| Analyst | Canaccord Genuity | Reiterates to buy | PT $29 | -0.5% | +1.6% | Read | |||||
| Analyst | Maxim Group | Reiterates to buy | PT $35 | -6.6% | -1.1% | — | |||||
| Analyst | Maxim Group | Reiterates to buy | PT $35 | -6.6% | -1.1% | Read | |||||
| Analyst | Guggenheim | Reiterates to buy | PT $29 | -6.6% | -1.1% | — | |||||
| Analyst | Guggenheim | Reiterates to buy | PT $29 | -6.6% | -1.1% | Read | |||||
| Analyst | BTIG | Reiterates to buy | PT $27 | -7.4% | +2.0% | — | |||||
| Analyst | BTIG | Reiterates to buy | PT $27 | -7.4% | +2.0% | Read |
1W / 1M / 6M = how ZVRA moved from the trade or filing date.
Insider trading in ZVRA: who is buying and selling
| Insider | Role | Trades | Open-market net | Shares held | Last trade |
|---|---|---|---|---|---|
| McFarlane Neil F. | President and CEO | 1 | -$224.95K | Oct 12, 2026 | |
| Rahsaan Thompson | Chief Legal & Compliance | 3 | -$438.18K | Jun 22, 2026 |
Analyst ratings on ZVRA
| Date | Firm | Action | Rating | Price target | 1W | 1M | 6M | Story |
|---|---|---|---|---|---|---|---|---|
| HC Wainwright | Reiterates | buy | $26 | +10.3% | -3.7% | Read | ||
| Canaccord Genuity | Reiterates | buy | $29 | -0.5% | +1.6% | Read | ||
| Canaccord Genuity | Reiterates | buy | $29 | -0.5% | +1.6% | Read | ||
| Maxim Group | Reiterates | buy | $35 | -6.6% | -1.1% | — | ||
| Maxim Group | Reiterates | buy | $35 | -6.6% | -1.1% | Read | ||
| Guggenheim | Reiterates | buy | $29 | -6.6% | -1.1% | — | ||
| Guggenheim | Reiterates | buy | $29 | -6.6% | -1.1% | Read | ||
| BTIG | Reiterates | buy | $27 | -7.4% | +2.0% | — | ||
| BTIG | Reiterates | buy | $27 | -7.4% | +2.0% | Read |
Frequently asked questions
Are ZVRA insiders buying or selling?
Over the last 12 months 0 insiders made 0 open-market purchases worth $0 and 2 insiders made 2 open-market sales worth $663.13K, a net -$663.13K.
What is the latest insider trade in ZVRA?
McFarlane Neil F., President and CEO filed a sell (open-market sale) of 20K sh worth $224.95K on Oct 12, 2026.
Other biotechnology stocks
Data comes from public SEC Form 4 and 13F filings and STOCK Act disclosures. Dates are the trade or filing date reported. This page is for research only and is not investment advice.
Get a text when insiders, Congress or big funds trade a stock.
Free. Reply STOP anytime.